Shots:
- Zymeworks has entered into a definitive agreement to acquire Theravance Biopharma, adding Yupelri, the only once-daily nebulized LAMA for COPD, to its partnered portfolio to strengthen long-term commercial cash flows
- As per the deal, Zymeworks will acquire Theravance for ~$929M, with Theravance’s shareholders receiving $17 per share in cash; closing is expected in H2’26
- The acquisition provides Zymeworks a 35% US net profit share in Yupelri, access to additional milestone & royalty opportunities, retained R&D assets & Irish tax attributes, while supporting its strategy of funding pipeline innovation through diversified commercial revenue streams
Ref: Globenewswire | Image: Theravance | Press Release
Related News: Zymeworks Raises $250M from Royalty Pharma Backed by Ziihera Royalties
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
